(c)OFER-TRABEC es un servicio ofrecido por el Centro de Comunicaciones RedIRIS
(Permitida la reproducción siempre que se cite la fuente de este Servicio).
***********************************************************************
***********************************************************************
Se agradece la colaboración en OFER-TRABEC del:
Centro de Información Administrativa de Presidencia del Gobierno
------------------------
---Procedencia:
Institución:Vall Hebron Institute of Oncology (VHIO)
Contacto correo-e:rrhh@vhio.net
---
The group of Joan Seoane within the Vall d'Hebron Institute of Oncology, Barcelona, is looking for a laboratory technician.
Our main field of interest is the understanding of the molecular mechanisms involved in the genesis and progression of glioma.
Glioma is the most common and aggressive tumour of the brain and its most malignant form, glioblastoma multiforme. The understanding of the molecular mechanisms involved in the biology of glioma is essential for the development of successful and rational therapeutic strategies. Our approach is based on a tight collaboration with clinical researchers of the Vall d'Hebron hospital and the study of patient-derived tumours. Moreover, we participate in ongoing clinical trials obtaining critical information about the biology of human tumours. We expect that our results will help understand the biology of glioma and cancer, and we aspire to translate our discoveries to a clinical ambit identifying molecular markers of diagnosis and prognosis, markers of response to therapies, and unveil new therapeutic targets against this deadly disease.
We are seeking a laboratory technician to work in collaborative research projects that will be involved both in genotyping and deep sequencing. The candidate will be scientifically involved and responsible for the projects that he/she is working on.
Candidates must have a strong background in molecular and cellular biology with at least 4 years of relevant laboratory experience, and high motivation. Experience in genomics will be considered. Fluency in English is required and computer literacy is essential.
Applicants should hold a Ph.D, B.Sc or M.Sc.
The application will be open until the position is filled.
Interested candidates, please send a letter of intention, CV, and two references to
Human Resources (rrhh@vhio.net)
----------------
Información complementaria de la oferta:
Selected references related to the field:
Pieter J.A. Eichhorn, Laura Rodón, Alba Gonzàlez-Juncà, Annette Dirac, Magüi Gili, Elena Martínez-Sáez, Claudia Aura, Ignasi Barba, Vicente Peg, Aleix Prat, Isabel Cuartas, Jose Jimenez, David García-Dorado, Juan Sahuquillo, Réné Bernards, José Baselga, Joan Seoane. "USP15 stabilizes the TGF-β receptor I and promotes oncogenesis through the activation of the TGF-β signal in glioblastoma" Nature Medicine (in press)
J. Anido, A. Sáez-Borderías, A. Gonzàlez-Juncà, L. Rodón, G.d Folch, M. A. Carmona, R. M. Prieto-Sánchez, I. Barba, E. Martínez-Sáez, L. Prudkin, I. Cuartas, C. Raventós, F. Martínez-Ricarte, M.A.Poca, D.García-Dorado, M.Lahn, J.Yingling, J.Rodón, J.Sahuquillo, J.Baselga, J. Seoane. "TGF-beta receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma" Cancer Cell (2010) 18, 655-668
S. Peñuelas, J. Anido, R. M. Prieto-Sánchez, G. Folch, I. Barba, I. Cuartas, D. García-Dorado, M. A. Poca, J. Sahuquillo, J. Baselga, J. Seoane "TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma" Cancer Cell (2009) 15, 315-27
A. Bruna, R.S. Darken, F. Rojo, A. Ocaña, S. Peñuelas, A. Arias, R. Paris, A. Tortosa, J. Mora, J. Baselga, J. Seoane, "High TGF-beta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene" Cancer Cell (2007) 11, 147-160
*************************************************************************
Para darse de baja OFER-TRABEC pinche y envíe:
mailto:OFER-TRABEC-signoff-request@listserv.rediris.es
*************************************************************************
No hay comentarios:
Publicar un comentario